Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Completed
Lexicon Pharmaceuticals
Phase 2
2009-03-01
The purpose of this study is to evaluate the safety and tolerability of telotristat etiprate
(LX1606) versus a placebo control in participants with symptomatic carcinoid syndrome not
managed by stable-dose long-acting octreotide therapy. Following determination of the
maximally tolerated or effective dose, cohort expansion will occur to confirm effect on
symptoms and safety profile.
Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome
Completed
Lexicon Pharmaceuticals
Phase 2
2010-06-15
The purpose of the study is to evaluate the safety and tolerability of orally administered
telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis
Completed
Lexicon Pharmaceuticals
Phase 2
2012-01-30
This is a multicenter, placebo-controlled, parallel-group, pilot study to evaluate safety and
preliminary effectiveness of two blinded dose levels of telotristat etiprate (LX1606) in
participants with acute, mild to moderate ulcerative colitis on 5-aminosalicylic
acid/mesalamine therapy.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
